Only Three in Nanjing! Nanjing Vcare’s Full-industry-chain Pilot Platform for Drug R&D Shortlisted in the 2025 Provincial Manufacturing Pilot Platform Proposed Upgrading List

2025-12-29

　　Recently, the Jiangsu Provincial Department of Industry and Information Technology publicized the 2025 Provincial Manufacturing Pilot Platform Proposed Upgrading List. The Full-industry-chain Pilot Platform for Drug R&D, independently built by Nanjing Vcare PharmaTech Co., Ltd. (Nanjing Vcare), was successfully shortlisted. Only three enterprises in Nanjing were selected for this list.

 

　　Focusing on the key pilot scale-up links in the R&D of innovative drugs and generic drugs, this professional pilot platform closely centers on the core demand of "from R&D to industrialization". It has established a full-chain service system covering CMC of innovative and generic drugs, clinical and registration services, as well as CRDMO for innovative drugs. The platform provides systematic and professional pilot solutions for global pharmaceutical enterprises and new drug R&D institutions, helping tackle the transformation challenges from laboratory bench-scale research to large-scale production. Equipped with more than 100 sets of advanced experimental facilities and multiple professional pilot production lines, it has delivered process development and pilot verification services for over 300 domestic and overseas biopharmaceutical enterprises.

 

　　Nanjing Vcare will continue to improve the pilot service system, increase R&D investment and technological upgrading, and further strengthen the leading and driving role of the pilot platform. Relying on the platform, the company will deepen its full-chain capabilities of "R&D – Pilot Testing – Industrialization", facilitate the transformation and landing of more innovative achievements, and contribute to the innovative development of the pharmaceutical industry and improved accessibility of medicines for patients.

Prev

Nanjing Vcare Approved to Establish Jiangsu Provincial Postdoctoral Innovation Practice Base

Next

Tianshu Pharmaceutical, Manufacturing Base of Nanjing Vcare, Has Its Near-term GHG Emission Reduction Targets Validated by SBTi